Home > Products> Chest Lung Cancer Drugs> Dabrafenib 50mg Capsules for BRAF V600+ Melanoma & NSCLC

Dabrafenib 50mg Capsules for BRAF V600+ Melanoma & NSCLC

Basic Information

Place of Origin:	Laos
Brand Name:	PHOTRAME 2
Model Number:	GSK2118436

Minimum Order Quantity:	1 PCS
Price:	Please contact a specialist WhatsApp：55342706
Packaging Details:	Negotiable
Delivery Time:	Negotiable
Payment Terms:	Western Union,MoneyGram,T/T
Supply Ability:	Negotiable

Get Best Price Contact Now

Detail Information

Specifications::	2mg*30 Tablets/bottle (box)	Indications:	Non-small Cell Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma
Target:	MEK1、MEK2、BRAF V600	Product Name:	Dabrafenib
Recommended Dose:	Please Follow Doctor's Advice	Storage:	Shade, Seal, And Store In A Dry Place Below 30°C.
Highlight:	2mg PHOTRAME photrame treatment drugs , 2mg photrame treatment drugs PHOTRAME , 2mg photrame PHOTRAME treatment drugs

Product Description

Dabrafenib (Tafinlar®) 50mg*28 Tablets

For treatment of Non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma (Stage 1, 2, 3)

Specifications	2mg*30 tablets/bottle (box)
Indications	Non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma
Target	MEK1, MEK2, BRAF V600
Recommended Dose	Please follow doctor's advice
Storage	Shade, seal, and store in a dry place below 30°C

Product Description

Drug Information

Generic name: Dabrafenib mesylate capsules

Product name: Tafinlar®

English name: Dabrafenib mesylate Capsules

Chinese Pinyin: Jiahuangsuan Dalafeini Jiaonang

Indications

BRAF V600 mutation-positive unresectable or metastatic melanoma
Combined with trametinib for treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
Postoperative adjuvant therapy for BRAF V600 mutation-positive stage III melanoma after complete resection

Dosage and Administration

Important: Must be used in medical institutions with experience in anti-tumor treatment. BRAF V600 mutation testing required before treatment.

Recommended dose: 150 mg twice daily (total daily dose of 300 mg)

Administration: Take at least 1 hour before or 2 hours after a meal, with approximately 12 hours between doses

Combination therapy: When combined with trametinib, both should be taken at the same time each day

Dosage Adjustment

Available in 50 mg and 75 mg strengths for dose adjustment needs
Treatment interruption, dose reduction, or discontinuation may be necessary for adverse reactions
For combination therapy toxicity, both treatments should be adjusted simultaneously

Special Populations

Hepatic impairment: No adjustment for mild impairment; use caution with moderate/severe impairment
Renal impairment: No adjustment for mild/moderate impairment; use caution with severe impairment
Pediatric use: Safety and effectiveness not established for patients under 18
Elderly: No initial dose adjustment required for patients over 65

Adverse Reactions

Monotherapy common reactions (≥20%): Keratoderma, headache, pyrexia, arthralgia, papilloma, alopecia, palmoplantar erythrodysesthesia syndrome (PPES)

Combination therapy: 11% discontinued treatment (most common: fever 1.9%); 26% required dose reduction (most common: fever 14%)

For complete safety information, consult the dabrafenib side effects reference.

Storage

Shade, seal, and store in a dry place below 30°C.